← Leaderboards
Brent John Small
University Of South Florida
$1,954,364
Attributed
$4,799,810
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,799,810 · 6
By mechanism
R01$4,131,406 · 2
R03$442,827 · 3
P01$225,577 · 1
Top collaborators
- Heather S.L. Jim5 shared
- Frederick Locke5 shared
- Brian D Gonzalez2 shared
- Michelle C Janelsins2 shared
- Stacey Beth Scott2 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Cecile A Lengacher$5,858,173
- Terrance L. Albrecht$10,498,908
- Rex M Philpot$711,274
- Timothy J Yeatman$17,520,103
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCognitiveExhibitsCancer SurvivorImpaired CognitionCellular PhoneEcological Momentary AssessmentInnovationSurvivorshipFuturePatient Outcomes AssessmentsCognitive PerformanceFatigueRisk FactorsQuality Of LifeLifeAttentionActigraphyQuestionnairesPerformanceBehavioralBiologicalCognitionModifiable Risk
Grant awards (18)
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$770,748
R01 · FY2025 · CA
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment$664,612
R01 · FY2025 · CA
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment$700,049
R01 · FY2024 · CA
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$160,118
R01 · FY2024 · CA
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$657,991
R01 · FY2023 · CA
Accelerated aging after chimeric antigen receptor T-cell therapy (CART): Leveraging a novel population of cancer survivors to elucidate mechanisms of dementia$470,597
R01 · FY2023 · CA
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$707,291
R01 · FY2022 · CA
Daily Cognitive Functioning Among Cancer Survivors$84,988
R03 · FY2016 · CA
Daily Cognitive Functioning Among Cancer Survivors$97,363
R03 · FY2015 · CA
STATISTICAL CORE$43,590
P01 · FY2010 · AG · contact PI
STATISTICAL CORE$43,406
P01 · FY2009 · AG · contact PI
STATISTICAL CORE$42,808
P01 · FY2008 · AG · contact PI
Apolipoprotein E Genotype and Cognitive Performance in Breast Cancer Survivors$59,466
R03 · FY2007 · CA · contact PI
STATISTICAL CORE$47,950
P01 · FY2007 · AG · contact PI
Apolipoprotein E Genotype and Cognitive Performance in Breast Cancer Survivors$72,541
R03 · FY2006 · CA · contact PI
STATISTICAL CORE$47,823
P01 · FY2006 · AG · contact PI
Lifestyle Activities and Changes in Cognitive Abilities$63,219
R03 · FY2005 · AG
Lifestyle Activities and Changes in Cognitive Abilities$65,250
R03 · FY2004 · AG